The acute management of venous thromboembolism in pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 13, Issue 6, 2001, Pages 569-575

  Greer, Ian A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; D DIMER; DALTEPARIN; DANAPAROID; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CESAREAN SECTION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; ECHOGRAPHY; EMBRYOPATHY; EPIDURAL HEMATOMA; FEMALE; HUMAN; LABOR; LUNG EMBOLISM; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; MAINTENANCE THERAPY; MATERNAL DISEASE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA;

ANTICOAGULANTS; CESAREAN SECTION; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LABOR, OBSTETRIC; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0035197590     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200112000-00004     Document Type: Review

References (53)

1. Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience
2. Thromboembolic disease associated with pregnancy: An 11 year review
3. Risk factors for pregnancy associated venous thromboembolism
4. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy
5. Haemostasis and thrombosis in pregnancy
6. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy
7. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism
8. Thrombosis in pregnancy: Maternal and fetal issues
9. Venous thrombosis: A multicausal disease
10. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy
11. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium
12. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism
13. Detection of DVT by real-time B-mode ultrasonography
14. Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
15. Diagnostic tests for deep vein thrombosis: Clinical usefulness depends on probability of disease
16. Non-haemorrhagic obstetric shock
17. Risks to the fetus of radiological procedures used in the diagnosis of maternal/venous thromboembolic disease
18. Anticoagulants in pregnancy: Fetal defects
19. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves
20. Peripartum prophylaxis of thromboembolism
21. Placental transport of heparin
22. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
23. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy
24. Safety of low-molecular-weight heparin in pregnancy: A systematic review
25. Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis
26. Thrombocytopenia antithrombin deficiency and extensive thromboembolism in pregnancy: Treatment with low molecular weight heparin
27. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
28. Hirudin, treatment in a breastfeeding woman
29. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
30. Heparin in the treatment of pulmonary thromboembolism
31. The clinical course of pulmonary embolism
32. Antithrombotic therapy for venous thromboembolic disease
33. Heparin
34. Treatment of venous thromboembolism
35. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
36. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep venous thrombosis: A meta-analysis
37. Low molecular weight heparin in the treatment of venous thromboembolism: An updated meta-analysis
38. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials
39. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism
40. Low molecular weight heparin for the immediate management of thromboembolic disease in pregnancy
41. Antifactor xa profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin for prevention and treatment of thromboembolism in pregnancy
42. Sixth ACCP consensus conference on antithrombotic therapy. Use of antithrombotic agents during pregnancy
43. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy
44. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
45. Long-term treatment of venous thromboembolism: The place of low molecular weight heparin
46. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
47. Guidelines on oral anticoagulation: Third edition
48. Central nerve block and thromboprophylaxis: Is there a problem?
49. Spinal and epidural blockade and perioperative low molecular weight heparin: Smooth sailing on the Titanic
50. Neuraxial block and low molecular weight heparin: Balancing perioperative analgesia and thromboprophylaxis